This is the current release of the guideline.

Treatment Guidelines

The goal of weight loss therapy for patients with cardiovascular disease (CVD) is to reduce or eliminate coronary heart disease (CHD) risk factors and improve cardiac function. Aggressive weight loss therapy could be harmful in selected patients, such as those who have had a recent myocardial infarction or stroke or who have unstable angina, and attempts at weight loss should be delayed until these patients are medically stable.

Clinical Evaluation

The physician's office should be an environment that is sensitive to the needs of obese patients. The waiting room should contain chairs without arms, large gowns and large blood pressure cuffs should be available, and a scale that can weigh patients who weigh >300 lb should be available and located in a private area. The initial assessment should include an appropriate history, physical examination, and laboratory tests.

History

In addition to a standard medical interview, a patient's history should include an assessment of (1) weight history (highest and lowest adult body weight, previous weight loss attempts, weight pattern, and potential triggers and social and environmental factors that contributed to weight gain), (2) dietary history, including an assessment of types and timing of meals and snacks and an attempt to identify possible triggers that result in excessive energy intake, (3) physical activity and function (daily and exercise activities, physical limitations, effect of obesity on physical lifestyle), (4) obesity-related health risk (age of onset and duration of obesity, family history of obesity and obesity-related medical complications, current obesity-related disease), (5) possible psychiatric illnesses, such as binge eating disorder and depression, that may require therapy before a weight loss program is initiated, and (6) ability to lose weight (desire to lose weight, weight loss goals and expectations, limitations for achieving weight loss, including medications and illnesses, lifestyle and work patterns, financial resources, and special needs).

Physical Examination

The patient's body-mass index (BMI) and waist circumference should be determined. BMI is generally correlated with percentage of body fat in a curvilinear fashion. Some people with an "obese" BMI, who have a normal amount of body fat and a large muscle mass, are not at increased risk for CHD, whereas people with a "normal" BMI, who have excessive body fat and small muscle mass, are at increased risk. Waist circumference, measured halfway between the last rib and the iliac crest, correlates with abdominal fat mass. The table below titled "Weight Classification by BMI" provides a classification of risk based on BMI. A waist circumference of >88 cm (35 in) for women and >102 cm (40 in) for men is associated with an increased risk of metabolic diseases and CHD. Additional assessments should include measuring blood pressure with a large cuff and searching for physical signs of right or left ventricular dysfunction, congestive heart failure, and pulmonary disease. An electronic stethoscope can increase a physician's ability to detect cardiac abnormalities in patients who are extremely obese.

Table: Weight Classification by BMI*

* Data from Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults -- The Evidence Report. National Institutes of Health. Obes Res. 1998;6:51S-209S.

Additional adiposity-related risk factors: waist circumference >40 (in men) and >35 (in women); weight gain of >5 kg since age 18-20 years.

Laboratory Tests

An electrocardiogram (ECG) is needed to check for evidence of CHD and to obtain a baseline tracing for future comparisons. Standard blood tests should be performed to search for CHD risk factors, including prediabetes (impaired fasting blood glucose or impaired glucose tolerance), dyslipidemia (increased triglycerides, low high density lipoprotein cholesterol [HDL-C], and increased low density lipoprotein cholesterol [LDL-C]), and the metabolic syndrome. Additional studies may be needed to further evaluate specific clinical suspicions based on the history and physical examination, such as sleep studies to diagnose obesity hypoventilation syndrome (OHS) or obstructive sleep apnea (OSA) and an exercise treadmill test or electron beam computerized tomography scanning or both to evaluate CHD risk. The comparative value of exercise tolerance testing and electron beam computerized tomography in obese subjects has not been determined. Exercise treadmill testing is not recommended for patients without cardiac symptoms, and neither exercise treadmill testing nor electron beam computerized tomography scanning should be performed in patients who are at low risk for CHD, based on clinical judgment or Framingham risk score.

Therapeutic Options

Appropriate management requires identifying patients who need treatment, developing a realistic treatment plan, and implementing a defined treatment strategy that can be modified as needed during long-term surveillance. The Practical Guide to the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults was developed by the North American Association for the Study of Obesity in conjunction with the National Heart, Lung, and Blood Institute. Suggested guidelines from the guide for selecting among different weight loss treatment options, based on disease risk, are shown in the table below titled "Weight Loss Treatment Guidelines." A typical clinical consultation involves a physician's giving advice without adequate consideration of the patient's priorities, motivation, or confidence in undertaking change. In contrast, obesity therapy should involve "patient-centered counseling," which encourages patients to set goals and express their own ideas for therapy, with input from the healthcare professional. The treatment plan also must take into account the patient's readiness for therapy and the patient's ability to comply with the proposed treatment plan. Realistic goals should be established and frequent follow-up visits should be scheduled to monitor progress, modify the treatment plan as needed, and provide encouragement. Effective therapy requires a long-term structured approach with continued support from the physician and other caregivers, particularly during periods of patient recidivism and weight regain.

Reducing energy intake is the cornerstone of weight management therapy. Providing appropriate nutrition counseling and the behavior modification therapy needed to implement dietary changes within the setting of a busy outpatient practice is difficult if not impossible for most physicians because they do not have the time or expertise to provide this kind of care. Therefore, referral to a reputable weight loss program or experienced dietitian should be considered, if these resources are available. Additional therapy with weight loss medications or bariatric surgery can be useful in properly selected patients.

Table: Weight Loss Treatment Guidelines*

* Data from Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults -- The Evidence Report. National Institutes of Health. Obes Res. 1998;6:51S-209S.
** Pharmacotherapy should be considered only in patients who are not able to achieve adequate weight loss by available conventional lifestyle modifications and who have no absolute contraindications for drug therapy.
*** Bariatric surgery should be considered only in patients who are unable to lose weight with available conventional therapy and who have no absolute contraindications for surgery.

None provided

The type of evidence supporting each recommendation is not specifically stated.

Not applicable: The guideline was not adapted from another source.

2004 Nov 2

American Heart Association - Professional Association

American Heart Association

Working Groups of the American Heart Association

Council on Nutrition, Physical Activity, and Metabolism

Council Members: Samuel Klein, MD; Lora E. Burke, RN, MPH, PhD; George A. Bray, MD; Steven Blair, PED; David B. Allison, PhD; Xavier Pi-Sunyer, MD; Yuling Hong, MD, PhD; Robert H. Eckel, MD

The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit.

American College of Cardiology Foundation - Medical Specialty Society

This is the current release of the guideline.

None available

None available

This NGC summary was completed by ECRI on January 19, 2005. The information was verified by the guideline developer on February 23, 2005.